GLP-1 Testosterone Effects: Do Semaglutide and Tirzepatide Raise Levels?
GLP-1 testosterone research points to modest improvements in men with obesity-related functional hypogonadism, especially when weight and insulin resistance improve. Compare the strongest semaglutide and tirzepatide evidence, current prices, and buyer checks before choosing a product or provider.
Short Answer: What GLP-1 Testosterone Research Shows
GLP-1 testosterone research suggests semaglutide, liraglutide, dulaglutide, and tirzepatide can raise total testosterone in men whose low levels are tied to obesity, type 2 diabetes, and metabolic dysfunction. The gains appear to track weight loss and improved insulin resistance more strongly than any proven direct androgen effect.
The practical signal is positive in metabolically compromised men, but neutral in a short controlled study of healthy men with normal testosterone. That makes testosterone improvement a possible secondary benefit of metabolic recovery, not proof that GLP-1 drugs directly stimulate testosterone production or replace a proper low-testosterone evaluation.
For compound details, start with the semaglutide guide and tirzepatide guide. Then compare current buying options on the semaglutide price table and tirzepatide price table.
Why Weight Loss Can Restore Testosterone
Functional hypogonadism can reflect reversible suppression of the hypothalamic-pituitary-gonadal axis. Visceral fat, insulin resistance, inflammation, altered adipokine signaling, and greater conversion of androgens to estrogens can all contribute. Two 2026 reviews estimate testosterone deficiency affects roughly 40% to 50%, or 35% to 50%, of men with obesity or type 2 diabetes.
Insulin resistance can also lower sex hormone-binding globulin, reducing total testosterone even when free testosterone changes less. Total and free measurements are not interchangeable. Current studies cannot cleanly separate a drug-specific testosterone effect from the effects of fat loss and improved metabolic health.
The Strongest Human Data: 215 Men on Incretin Therapy
The clearest current dataset is the 2026 Endocrine Practice study by Portillo-Canales and colleagues. This retrospective study reviewed men ages 18 to 89 treated from 2021 through 2024. It included 215 men with paired total-testosterone measurements and 61 with paired free-testosterone measurements. Men using androgen-related therapy were excluded.
The group’s mean age was 55 ± 11 years, mean BMI was 36.3 ± 7.1 kg/m², and 77% had type 2 diabetes. After incretin therapy, mean weight loss was 5% and hemoglobin A1c fell 0.7 ± 1.6 percentage points, with P < .001.
Mean total testosterone increased from 332 ± 134 to 399 ± 152 ng/dL, also with P < .001. That is an average increase of 67 ng/dL. In the smaller paired subset, mean free testosterone rose from 6.9 ± 3.0 to 8.0 ± 4.2 ng/dL, P = .006.
The share of men with normal total testosterone increased from 67% to 86%, P < .001. Weight change correlated with total-testosterone change at r = -0.28, P < .001, and with free-testosterone change at r = -0.26, P = .04.
Those are useful real-world results, but they show association rather than randomized causation. The analysis mixed incretin drugs together, and the largest testosterone gains appeared in men who lost the most weight. The strongest reading is that better metabolic health often accompanies better hormone markers.
Semaglutide, Tirzepatide, and Healthy-Men Data Compared
A 2026 PRISMA review of eight studies found modest testosterone gains in men with obesity, type 2 diabetes, or functional hypogonadism, but no significant endocrine or reproductive effect in healthy men with normal testosterone. Only one included study was a randomized placebo-controlled crossover trial. Six were observational or interventional studies.
A broader 2026 systematic review assessed 29 publications, including 14 primary studies. Across incretin-based studies, mean total-testosterone increases ranged from 2.5 to 5.2 nmol/L. The authors judged the evidence heterogeneous and largely mediated by weight loss and improved insulin resistance. The randomized trials were small, with 12 to 42 participants and follow-up lasting 12 to 24 weeks.
That pattern matters more than any single headline. Men starting with metabolic dysfunction and low testosterone have room for several connected markers to improve together. Men who begin lean, metabolically healthy, and eugonadal do not show the same signal.
There is also no decisive head-to-head testosterone trial showing that tirzepatide is better than semaglutide for this outcome. Choose between them using the outcomes with more mature evidence, including weight loss, glucose control, tolerability, cost, and format. Treat a testosterone increase as a possible additional benefit, not the sole reason to select one compound.
The tirzepatide pilot included 83 men with obesity and metabolic hypogonadism, with a mean age of 55.3 ± 5.5 years. Researchers assigned 28 men to tirzepatide, 30 to no drug, and 25 to transdermal testosterone. The tirzepatide group used 2.5 mg weekly during month one and 5 mg from month two, with assessment at two months.
Compared with the other groups, the tirzepatide group showed significantly greater improvements in weight, waist circumference, fat mass, lean mass, IIEF-5 score, luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin, and total, free, and bioavailable testosterone. The abstract does not provide every numeric hormone change. A short, non-randomized 83-person pilot is encouraging, but not definitive proof.
The healthy-men trial provides an important control. Of 26 randomized healthy, normal-weight, eugonadal men ages 18 to 50, 24 completed a four-week dulaglutide-versus-placebo crossover trial. The total-testosterone difference was 0.9 nmol/L, with a 95% confidence interval from -1.5 to 3.3. The sexual-desire difference was 0.58, with a 95% confidence interval from -0.83 to 2.00 and P = .402.
The follicle-stimulating hormone difference was -0.2 IU/L, 95% CI -0.3 to 0.0, and the luteinizing hormone difference was -0.8 IU/L, 95% CI -1.5 to 0.0. Hormones along the hypothalamic-pituitary-gonadal axis and sperm parameters remained normal, with no significant treatment differences and no severe adverse events.
The comparison is straightforward: evidence is strongest for metabolic recovery in men starting with obesity-related low testosterone, not for boosting levels that are already normal.
Testosterone, Fertility, and TRT Are Different Questions
A September 2026 structured review found that total testosterone often increased in metabolically impaired men, while free-testosterone findings were inconsistent. Available small, short-term studies did not show the marked suppression of luteinizing hormone and follicle-stimulating hormone expected with exogenous testosterone.
That does not prove a fertility benefit. The review found no adequately powered GLP-1-specific prospective study that prespecified sperm DNA fragmentation, natural conception, assisted-reproduction outcomes, clinical pregnancy, or live birth. It also found no eligible controlled tirzepatide-specific study assessing semen or clinical fertility outcomes.
A higher testosterone result does not automatically mean better fertility, libido, erectile function, muscle retention, or symptom resolution. Each is a separate outcome with its own evidence. Semaglutide and tirzepatide also are not substitutes for testosterone replacement therapy. Persistent symptoms and repeatedly low morning measurements call for a clinician-led evaluation that distinguishes functional metabolic suppression from primary testicular or pituitary disease.
Body composition deserves attention during substantial weight loss regardless of hormone results. Resistance training, adequate protein, and body-composition monitoring help preserve the benefit you are pursuing. Our guide to GLP-1 muscle loss and lean mass explains that tradeoff in detail.
The right takeaway is specific: metabolic improvement may help normalize testosterone when metabolic dysfunction is the driver. It does not answer every reproductive or endocrine question.
Current Semaglutide and Tirzepatide Buyer Comparison
These prices come from the October 14, 2026 catalog snapshot. Inventory, codes, and checkout totals move, so recheck the live tables before buying.
Current semaglutide research-vial examples:
- RetaOne: 20 mg for $39 list, or $37.05 after 5% with peptidepub, about $1.85/mg.
- Glacier: 15 mg for $40.49 list, or $36.44 after 10% with PEPTIDEPUB, about $2.43/mg.
- Puratek: 10 mg for $34.95 with no cataloged code, about $3.50/mg.
- Ascension: 5 mg for $38 list, or $19 after 50% with PEPTIDEPUB, equal to $3.80/mg.
Compare the live semaglutide price per mg, then use the cost-per-dose tool to test value at the amount and frequency relevant to your comparison. The lowest vial price is not always the lowest cost per milligram, and neither number establishes product quality.
Readers who prefer clinician-led access can review the verified EnhanceMD semaglutide route. Keep the broader provider comparison nearby so you can check clinician involvement, pharmacy disclosure, all-in pricing, refill terms, and cancellation policy rather than comparing a headline monthly number alone.
Current tirzepatide research-vial examples:
- Puratek: 60 mg for $89.95 with no cataloged code, about $1.50/mg.
- NextGen: 60 mg for $100 list, or $90 after 10% with peptidepub, equal to $1.50/mg.
- RetaOne: 60 mg for $117 list, or $111.15 after 5% with peptidepub, about $1.85/mg.
- Glacier: 60 mg for $168.99 list, or $152.09 after 10% with PEPTIDEPUB, about $2.53/mg.
- Ascension: 30 mg for $180 list, or $90 after 50% with PEPTIDEPUB, equal to $3.00/mg.
Use the live tirzepatide price table and current deals page before checkout. For clinician-led access, compare the verified EnhanceMD tirzepatide route against the terms on the provider directory.
For a research-vial purchase, require the exact molecule, a lot number matching current inventory, a named independent lab, identity, purity, quantitative net content, and sterility or endotoxin evidence where available. Vendor-level testing is useful screening information, but it does not prove the vial in your cart.
The vendor directory shows current evidence, and PeptidePub’s methodology explains how the proof is scored. Review how to read a peptide COA before choosing a cheap vial over a better-documented one. Price matters most after identity, quantity, and lot matching clear the check.
FAQ
Do GLP-1 drugs raise testosterone?
In men with obesity-related functional hypogonadism, current studies show modest average gains that track weight loss and metabolic improvement. They do not reliably raise testosterone in healthy men with normal baseline levels.
How much did testosterone rise in the 2026 study?
Mean total testosterone rose from 332 to 399 ng/dL, a 67 ng/dL increase. Mean free testosterone rose from 6.9 to 8.0 ng/dL in the smaller paired subset.
Is tirzepatide better than semaglutide for testosterone?
There is no decisive head-to-head testosterone trial. Tirzepatide has a positive 83-person controlled pilot, while the broader evidence combines multiple GLP-1 drugs and is too heterogeneous to rank them for this outcome. Our semaglutide versus tirzepatide guide compares the more established buying factors.
Can semaglutide or tirzepatide replace TRT?
No. They may improve functional low testosterone when metabolic dysfunction is the driver, but they are not testosterone replacement and do not address every cause of hypogonadism.
Do GLP-1 drugs improve male fertility?
Evidence is too limited. Reviews found small, heterogeneous semen studies and no adequately powered prospective trials for natural conception, assisted reproduction, clinical pregnancy, or live birth.
Bottom Line
The clearest GLP-1 testosterone benefit signal belongs to men with obesity, type 2 diabetes, and functional low testosterone. Current evidence supports metabolic recovery, not a guaranteed direct testosterone-boosting effect.
Compare semaglutide and tirzepatide using outcomes with mature evidence, including weight loss, glucose control, tolerability, cost, and format. Treat testosterone improvement as a possible secondary benefit rather than the sole buying reason. For more context beyond weight loss, see GLP-1 benefits under study.
Before checkout, compare live semaglutide prices and tirzepatide prices, inspect exact-lot evidence through the vendor directory, and check active deals. Use the provider directory if clinician-led access is the better fit.
Recheck the October 14 prices before buying. A low price never substitutes for identity, quantitative content, and lot-matched testing.
Sources
Follow @PeptidePub on X for daily peptide price drops.
Get peptide price-drop alerts
Set a target price and we'll email you when a trusted, third-party-tested vendor drops below it. No spam, unsubscribe anytime.